Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1358894 in CCK-4 Induced Panic Symptoms
NCT03904576Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bi 1358894 in major depressive disorder (MDD), borderline personality disorder (BPD) and panic disorder (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum Change From Baseline in Panic Symptom Scale (PSS) Sum Intensity Score at 192 hours. Started Apr 2019; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)panic disorder
Beyond the preview
Go deeper on NCT03904576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904576.